Gahlinger PM. Club drugs: MDMA, gamma-hydroxybutyrate (GHB), rohypnol, and ketamine. Am Fam Physician. 2004;69:2619-2627.
Spivey WH. Flumazenil and seizures: analysis of 43 cases. Clin Ther. 1992;14:292-305.
1. Hojer J, Baehrendtz S. The effect of flumazenil (Ro 15-1788) in the management of self-induced benzodiazepine poisoning. A double-blind controlled study. Acta Med Scand. 1988;224:357-365.
2. Gahlinger PM. Club drugs: MDMA, gamma-hydroxybutyrate (GHB), rohypnol, and ketamine. Am Fam Physician. 2004;69:2619-2627.
3. Lechevallier-Michel N, Berr C, Fourrier-Reglat A. Incidence and characteristics of benzodiazepine use in an elderly cohort: the EVA study. Therapie. 2005;60:561-566.
4. Gleason PP, Schulz R, Smith NL, et al. Correlates and prevalence of benzodiazepine use in community-dwelling elderly. J Gen Intern Med. 1998;13:243-250.
5. Valenstein M, Khanujua Taylor K, Austin K, et al. Benzodiazepine use among depressed patients treated in mental health settings. Am J Psychiatry. 2004;161:654-661.
6. Guina J, Rossetter SR, DeRhodes BJ, et al. Benzodiazepines for PTSD: a systematic review and meta-analysis. J Psychiatr Pract. 2015;21:281-303.
7. Brunoni AR, Nunes MA, Figueiredo R, et al. Patterns of benzodiazepine and antidepressant use among middle-aged adults: the Brazilian longitudinal study of adult health (ELSA-Brasil). J Affect Disord. 2013;151:71-77.
8. Préville M, Vasiliadis HM, Bossé C, et al. Pattern of psychotropic drug use among older adults having a depression or an anxiety disorder: results from the longitudinal ESA study. Can J Psychiatry. 2011;56:348-357.
9. Saarelainen L, Tolppanen AM, Koponen M, et al. Risk of hip fracture in benzodiazepine users with and without Alzheimer disease. J Am Med Dir Assoc. 2017;18:87;e15-e87;e21.
10. Taipale H, Koponen M, Tanskanen A, et al. Use of benzodiazepines and related drugs is associated with a risk of stroke among persons with Alzheimer's disease. Int Clin Psychopharmacol. 2017;32:135-141.
11. Huang WS, Muo CH, Chang SN, et al. Benzodiazepine use and risk of stroke: a retrospective population-based cohort study. Psychiatry Clin Neurosci. 2014;68:255-262.
12. Buckley NA, Dawson AH, Whyte IM, et al. Relative toxicity of benzodiazepines in overdose. BMJ. 1995;310:219-221.
13. Warner M, Trinidad JP, Bastian BA, et al. Drugs most frequently involved in drug overdose deaths: United States, 2010-2014. Natl Vital Stat Rep. 2016;65:1-15.
14. Bachhuber MA, Hennessy S, Cunningham CO, et al. Increasing benzodiazepine prescriptions and overdose mortality in the United States, 1996-2013. Am J Public Health. 2016;106:686-688.
15. Hawton K, Bergen H, Casey D, et al. Self-harm in England: a tale of three cities. Multicentre study of self-harm. Soc Psychiatry Psychiatr Epidemiol. 2007;42:513-521.
16. Ticehurst S, Carter GL, Clover KA, et al. Elderly patients with deliberate self-poisoning treated in an Australian general hospital. Int Psychogeriatr. 2002;14:97-105.
17. Okamoto R, Itoh Y, Murata Y, et al. Reduction of group II metabotropic glutamate receptors during development of benzodiazepine dependence. Pharmacology. 2013;91:145-152.
18. Backmund M, Meyer K, Henkel C, et al. Co-consumption of benzodiazepines in heroin users, methadone-substituted and codeine-substituted patients. J Addict Dis. 2005;24:17-29.
19. Man LH, Best D, Gossop M, et al. Relationship between prescribing and risk of opiate overdose among drug users in and out of maintenance treatment. Eur Addict Res. 2004;10:35-40.
20. Gahlinger PM. Illegal drugs: A complete guide to their history, chemistry, use and abuse. New York: Penguin (Plume); 2004.
21. Olfson M, King M, Schoenbaum M. Benzodiazepine use in the United States. JAMA Psychiatry. 2015;72:136-142.
22. Lugoboni F, Mirijello A, Faccini M, et al. Quality of life in a cohort of high-dose benzodiazepine dependent patients. Drug Alcohol Depend. 2014;142:105-109.
23. Harnod T, Lin CL, Sung FC, et al. An association between benzodiazepine use and occurrence of benign brain tumors. J Neurol Sci. 2014;336:8-12.
24. Vozoris NT, Fischer HD, Wang X, et al. Benzodiazepine use among older adults with chronic obstructive pulmonary disease: a population-based cohort study. Drugs Aging. 2013;30:183-192.
25. Billioti de Gage S, Moride Y, Ducruet T, et al. Benzodiazepine use and risk of Alzheimer's disease: case-control study. BMJ. 2014;349:g5205.
26. Konopka A, Pełka-Wysiecka J, Grzywacz A, et al. Psychosocial characteristics of benzodiazepine addicts compared to not addicted benzodiazepine users. Prog Neuropsychopharmacol Biol Psychiatry. 2013;40:229-235.
27. Willems IA, Gorgels WJ, Oude Voshaar RC, et al. Tolerance to benzodiazepines among long-term users in primary care. Fam Pract. 2013;30:404-410.
28. McCabe SE, West BT. Medical and nonmedical use of prescription benzodiazepine anxiolytics among US high school seniors. Addict Behav. 2014;39:959-964.
29. Janhsen K, Roser P, Hoffmann K. The problems of long-term treatment with benzodiazepines and related substances. Dtsch Arztebl Int. 2015;112:1-7.
30. Wu AH, McKay C, Broussard LA, et al. National Academy of Clinical Biochemistry laboratory medicine practice guidelines: recommendations for the use of laboratory tests to support poisoned patients who present to the emergency department. Clin Chem. 2003;49:357-379.
31. Haverkos GP, DiSalvo RP, Imhoff TE. Fatal seizures after flumazenil administration in a patient with mixed overdose. Ann Pharmacother. 1994;28:1347-1349.
32. Spivey WH. Flumazenil and seizures: analysis of 43 cases. Clin Ther. 1992;14:292-305.
33. Velluti R, Pedemonte M. Differential effects of benzodiazepines on cochlear and auditory nerve responses. Electroencephalogr Clin Neurophysiol. 1986;64:556-562.
34. Bezchlibnyk-Butler JZ, Jeffries JJ. Clinical handbook of psychotropic drugs, 16th ed. Toronto, Canada: Hogrefe & Huber Publishing; 2006.
35. Ngo AS, Anthony CR, Samuel M, et al. Should a benzodiazepine antagonist be used in unconscious patients presenting to the emergency department? Resuscitation. 2007;74:27-37.
36. Kyong YY, Park JT, Choi KH. Serial monitoring of sedation scores in benzodiazepine overdose. Am J Emerg Med. 2014;32:1438;e5-e6.
37. Vale JA, Kulig K; American Academy of Clinical Toxicology; European Association of Poisons Centres and Clinical Toxicologists. Position paper: gastric lavage. J Toxicol Clin Toxicol. 2004;42:933-943.
38. Chyka PA, Seger D. Position statement: single-dose activated charcoal. American Academy of Clinical Toxicology; European Association of Poisons Centres and Clinical Toxicologists. J Toxicol Clin Toxicol. 1997;35:721-741.
使用此内容应接受我们的免责声明。
BMJ临床实践的持续改进离不开您的帮助和反馈。如果您发现任何功能问题和内容错误,或您对BMJ临床实践有任何疑问或建议,请您扫描右侧二维码并根据页面指导填写您的反馈和联系信息*。一旦您的建议在我们核实后被采纳,您将会收到一份小礼品。
如果您有紧急问题需要我们帮助,请您联系我们。
邮箱:bmjchina.support@bmj.com
电话:+86 10 64100686-612
*您的联系信息仅会用于我们与您确认反馈信息和礼品事宜。
BMJ临床实践官方反馈平台